University of Texas, Health Science Center at San Antonio, Division of Infectious Diseases, Department of Medicine, San Antonio, TX 78229-3900, USA.
Expert Opin Drug Metab Toxicol. 2010 Jan;6(1):83-94. doi: 10.1517/17425250903463878.
Voriconazole is an extended-spectrum triazole developed specifically to target Aspergillus spp. and is now indicated as primary therapy in this circumstance. However, it has a broad spectrum of activity against both yeasts and molds and is also a viable treatment option in the treatment of other mycoses.
This review discusses the mechanism of action, the pharmacodynamics and pharmacokinetics and the most common mechanisms of resistance to this agent. An overview of therapeutic drug monitoring, drug-drug interactions and pivotal trials are also reviewed.
The reader will gain further knowledge of the unique aspects of voriconazole compared to other currently available antifungal agents.
Voriconazole offers distinct advantages over several other antifungals. The side effect profile of voriconazole is unique compared to other triazole agents. Concern for drug-drug interactions due to a frequently shared common metabolic pathway has prompted heightened interest in the use of therapeutic drug monitoring for concerns of toxicity, drug-drug interactions and in attempts to ensure efficacy. These aspects as well as a review of important clinical information pertaining to voriconazole are discussed here.
伏立康唑是一种广谱三唑类药物，专门针对曲霉菌属开发，目前是这种情况下的主要治疗药物。然而，它对酵母和霉菌都有广泛的活性，也是治疗其他真菌感染的可行治疗选择。
本综述讨论了该药物的作用机制、药效学和药代动力学以及针对该药物最常见的耐药机制。还综述了治疗药物监测、药物相互作用和关键试验。
读者将获得与其他现有抗真菌药物相比，伏立康唑独特方面的更多知识。
伏立康唑与其他几种抗真菌药物相比具有明显优势。与其他三唑类药物相比，伏立康唑的副作用谱是独特的。由于共同的常见代谢途径，药物-药物相互作用的问题引起了人们的高度关注，这促使人们对治疗药物监测的使用产生了浓厚的兴趣，以解决毒性、药物-药物相互作用的问题，并试图确保疗效。本文讨论了这些方面以及与伏立康唑相关的重要临床信息的综述。
